LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
LEXINGTON, Mass., Sept. 01, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the following upcoming investor conferences in New York City:
- The NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 11:00 a.m. ET.
- The Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016, at 2:50 p.m. ET.
- CL King’s Best Ideas Conference on Tuesday, September 13, 2016 at 8:45 a.m. ET.
Live, listen-only webcasts of the presentations may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. Replays of the webcasts will be available shortly after the conclusion of the presentations and will be archived on the Company's website for 30 days.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
Media Contact: Susan Heins, Pure Communications [email protected] 864-286-9597 Investor Contact: Matt Clawson, Pure Communications [email protected] 949-370-8500
